In the Poster Session dedicated to genitourinary cancers held on Sunday, June 2, 2024, at this year’s American Society of Clinical Oncology Annual Meeting in Chicago, Dr. Alicia Morgans presented a post hoc analysis of the ARAMIS trial of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), which aimed to assess the association between prostate-specific antigen (PSA) kinetics and radiological progression in this population. ...
nmCRPC
Advertisement
Latest News
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
A clinical trial sought to determine if flutamide is more effective with or without PROSTVAC in patients with nmCRPC.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA.
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.